Brief: Celularity Receives Fast Track Tag From U.S. FDA For Cell Therapy Candidate Cynk-101 For Advanced Her2/Neu Positive Gastric And Gastroesophageal Junction Cancers

Celularity

18/01/2022 13:36

Jan 18 (Reuters) - Celularity Inc  CELU.O :
    * CELULARITY RECEIVES FAST TRACK DESIGNATION FROM U.S. FDA
FOR ITS
NK CELL THERAPY CYNK-101 IN DEVELOPMENT FOR FIRST-LINE TREATMENT
OF ADVANCED HER2/NEU POSITIVE GASTRIC AND GASTROESOPHAGEAL
JUNCTION CANCERS
    * CELULARITY INC - PHASE 1/2A CLINICAL TRIAL WILL EVALUATE
SAFETY
AND PRELIMINARY EFFICACY OF CYNK-101
    * CELULARITY INC - SAFETY AND EFFICACY OF CYNK-101 HAVE NOT
BEEN
ESTABLISHED
    * CELULARITY INC - CYNK-101 HAS NOT BEEN APPROVED FOR ANY
USE BY
U.S. FOOD AND DRUG ADMINISTRATION OR ANY OTHER ANALOGOUS
REGULATORY AUTHORITY

Source text for Eikon:  ID:nGNX74lW9s 
Further company coverage:  CELU.O 

 ((Reuters.Briefs@thomsonreuters.com;))